About Scleroderma Treatment
Scleroderma is an autoimmune disorder, which is a condition when body’s tissues get attacked by the immune system. The term scleroderma is defined as the hardening of the skin; however, it is much more than the skin disorder. The disease is characterized by microvascular injury and fibrosis in the affected organs.
Technavio’s analysts forecast the global scleroderma treatment market to grow at a CAGR of 7.02% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global scleroderma treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Scleroderma Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Pfizer
Other prominent vendors
• Amgen
• Bayer AG
• Boehringer Ingelheim
• Biogen
• CELGENE
• Corbus Pharmaceuticals
• Johnson & Johnson
• Merck
• Novartis
• Sanofi
Market driver
• High unmet medical needs
• For a full, detailed list, view our report
Market challenge
• Unknown pathogenesis of the disorder
• For a full, detailed list, view our report
Market trend
• Partnerships and strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
• Scleroderma disease overview
• Market landscape
• Market overview
• Five forces analysis
PART 05: Pipeline landscape
PART 06: Market segmentation by drug class
• Anti-inflammatory drugs
• Immunosuppressants
• Others
• PDE5 inhibitors
• Calcium channel blockers
PART 07: Geographical segmentation
• Scleroderma treatment market in Americas
• Scleroderma treatment market in EMEA
• Scleroderma treatment market in APAC
PART 08: Decision framework
PART 09: Drivers and challenges
• Market drivers
• Market challenges
PART 10: Market trends
• Partnerships and strategic alliances
• Introduction of stem cells in scleroderma treatment
• Advent of novel therapies
PART 11: Vendor landscape
• Competitive scenario
PART 12: Key vendor analysis
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Pfizer
• Other prominent vendors
PART 13: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Types of scleroderma
Exhibit 02: Global scleroderma treatment market snapshot
Exhibit 03: Global scleroderma treatment market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global scleroderma treatment market
Exhibit 05: Five forces analysis
Exhibit 06: Number of pipeline molecules by vendors at various phases
Exhibit 07: Key clinical trials
Exhibit 08: Global scleroderma treatment market by drug class
Exhibit 09: Side effects associated with anti-inflammatory drug class
Exhibit 10: Global scleroderma anti-inflammatory drugs market 2016-2021 ($ millions)
Exhibit 11: Drivers and challenges of anti-inflammatory drugs
Exhibit 12: Side effects associated with immunosuppressants
Exhibit 13: Global scleroderma immunosuppressants market 2016-2021 ($ millions)
Exhibit 14: Drivers and challenges of immunosuppressants
Exhibit 15: Global scleroderma treatment market by others drug class 2016-2021 ($ millions)
Exhibit 16: Major drug classes included in the others segment
Exhibit 17: Side effects associated with PDE5 inhibitors
Exhibit 18: Global scleroderma PDE5 inhibitors market 2016-2021 ($ millions)
Exhibit 19: Drivers and challenges of PDE5 inhibitors
Exhibit 20: Side effects associated with calcium channel blockers
Exhibit 21: Global scleroderma calcium channel blockers market 2016-2021 ($ millions)
Exhibit 22: Drivers and challenges of calcium channel blockers
Exhibit 23: Global scleroderma treatment market segmentation based on geography 2016 and 2021 (%)
Exhibit 24: Global scleroderma treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 25: Market scenario in Americas
Exhibit 26: Scleroderma treatment market in Americas 2016-2021 ($ millions)
Exhibit 27: Market scenario in EMEA
Exhibit 28: Scleroderma treatment market in EMEA 2016-2021 ($ millions)
Exhibit 29: Market scenario in APAC
Exhibit 30: Scleroderma treatment market in APAC 2016-2021 ($ millions)
Exhibit 31: Promising new projects in scleroderma studies
Exhibit 32: Potential therapeutic targets involved in numerous studies for scleroderma
Exhibit 33: Strategic success factors of companies in global scleroderma treatment market
Exhibit 34: AstraZeneca: Key highlights
Exhibit 35: AstraZeneca: Strength assessment
Exhibit 36: AstraZeneca: Strategy assessment
Exhibit 37: AstraZeneca: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: GlaxoSmithKline: Key highlights
Exhibit 43: GlaxoSmithKline: Strength assessment
Exhibit 44: GlaxoSmithKline: Strategy assessment
Exhibit 45: GlaxoSmithKline: Opportunity assessment
Exhibit 46: Pfizer: Key highlights
Exhibit 47: Pfizer: Strength assessment
Exhibit 48: Pfizer: Strategy assessment
Exhibit 49: Pfizer: Opportunity assessment
